Anzeige
Mehr »
Login
Samstag, 24.07.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Breaking News: TAAT Global räumt jetzt richtig ab!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
78 Leser
Artikel bewerten:
(0)

Ablynx: ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.

REGULATED INFORMATION

GHENT, Belgium, 12 August 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Adrianus van Herk and Van Herk Investments B.V.

Van Herk Investments B.V. notified Ablynx that they have crossed the 5% threshold on 9 August 2016 as a result of the acquisition of Ablynx shares, including 1,835,276 Ablynx shares previously held by Adrianus van Herk. As a result of the transactions, Adrianus van Herk no longer holds Ablynx shares with Van Herk Investments B.V. now holding 3,290,357 Ablynx shares. The latter representing a 5.40% of the current 60,910,744 outstanding Ablynx shares.

Van Herk Investments B.V. is controlled by Adrianus van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors (http://www.ablynx.com/investors/share-information/major-shareholders/).

About Ablynx

Ablynx (http://www.ablynx.com/) is a biopharmaceutical company engaged in the development of Nanobodies® (http://www.ablynx.com/technology-innovation/understanding-nanobodies/), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes (http://www.ablynx.com/rd-portfolio/overview/) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com (http://www.ablynx.com).

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com (mailto:edwin.moses@ablynx.com)

Marieke Vermeersch
Director IR & Corporate Communications
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com (mailto:marieke.vermeersch@ablynx.com%20)
Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx@fticonsulting.com (mailto:ablynx@fticonsulting.com)


pdf format of the press release (http://hugin.info/137912/R/2034769/757794.pdf)



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#2034769
Kostenloser Wertpapierhandel auf Smartbroker.de
© 2016 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.